Sonim shareholders approve reverse stock split, authorized share increase, and equity plan expansion

DNA X, Inc.

Approved reverse stock split at ratio of 1-for-2 to 1-for-15, at Board discretion, within one year.
Approved increase in authorized common stock from 100M to 200M shares, at Board discretion within one year.
Approved amendment to 2019 Equity Incentive Plan adding 3,000,000 shares for issuance.
Stockholders did NOT approve proposal to limit officer liability under Delaware law.
Re-elected five directors and ratified Moss Adams as independent auditor for FY2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.